NCT02829684 Register of Patients With Prader-Willi Syndrome
| NCT ID | NCT02829684 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Prader-Willi Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2009-03 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2009-03 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prader-Willi Syndrome (PWS) is a rare syndrome with a prevalence of 15 to 20 000 at birth. PWS represents a large fraction of mental retardation syndromes due to a genetic cause and the most frequent cause of genetic obesity. The majority of the patients are seen by paediatricians. This syndrome is responsible for severe physical, psychological and social impairments. The diversity and the severity of the manifestations of this disease explain the requirement of multidisciplinary care which deserve specific evaluation. Today the follow-up and management of a great proportion of these patients are greatly insufficient if not absent. Teams strongly lack information on the natural history of this severe disease and on the factors involved in its evolution and the outcome of these patients throughout life. The present project is to implement a register in the whole country for children and adult patients
Eligibility Criteria
Inclusion Criteria: * all subjects with a Prader-Willi Syndrome Exclusion Criteria: \-
Contact & Investigator
TAUBER Maité, MD PhD
✉ tauber.m@chu-toulouse.frTauber Maité, MD
PRINCIPAL INVESTIGATOR
University Hospital, Toulouse
Frequently Asked Questions
Who can join the NCT02829684 clinical trial?
This trial is open to participants of all sexes, studying Prader-Willi Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02829684 currently recruiting?
Yes, NCT02829684 is actively recruiting participants. Contact the research team at tauber.m@chu-toulouse.fr for enrollment information.
Where is the NCT02829684 trial being conducted?
This trial is being conducted at Toulouse, France.
Who is sponsoring the NCT02829684 clinical trial?
NCT02829684 is sponsored by University Hospital, Toulouse. The principal investigator is Tauber Maité, MD at University Hospital, Toulouse. The trial plans to enroll 500 participants.